Co-Chairs: Holly Posner, MD; Philip Harvey, PhD

The goals of this working group continue to be further understanding the challenges in assessing for meaningful improvement or decrement in cognition during the 6 month to 2 year period of a typical clinical trial of AD and its precursors.  This includes thinking within the context of re-analyzing existing clinical trial data to enhance signal detection of existing psychometric instruments from pooled assessments using sophisticated statistical techniques. We will also present the latest data on assessment developments in cognitive neuroscience that may inform assessment development in the future. We also are working to further our awareness of the full cognitive profile of people who might enroll in such trials and to expand understanding of assessment of areas where potential treatment-related improvements may be clinically significant.